[Market Focus] Shaperon Surges on News of Key Immuno-Oncology Patent Registration

Shaperon is experiencing a strong performance on October 15 following news of a key patent registration for its immuno-oncology technology.

As of 10:18 a.m. on this day, Shaperon shares were trading at 2,515 won on the KOSDAQ market, up 6.79% from the previous trading day. The stock opened at 2,385 won and, after surging to as high as 2,655 won during the session, has slightly pulled back.

On this day, Shaperon announced that it had completed the registration of a patent for its core immuno-oncology pipeline technology, the "CD47 single-domain antibody." This patented technology blocks the "Don't eat me" signal of the CD47 protein, which is expressed by cancer cells to evade attacks from immune cells, thereby preventing cancer cells from suppressing the function of immune cells.

With this patent secured, the company explained that the intellectual property portfolio of the NanoMab-based bispecific antibody "Papiliximab" has been further advanced, bringing it closer to commercialization. Through this patent registration, Shaperon has now secured all the core technologies for its next-generation immuno-oncology platform, including the PD-L1 single-domain antibody, the CD47 single-domain antibody, and the bispecific antibody that simultaneously inhibits both PD-L1 and CD47.